Daily Brief Health Care: Aragen Life Sciences Limited, Shenzhen Salubris Pharmaceuticals, Scan.com and more

• BIOSECURE Act tailwinds are directionally real but commercially lagged: While WuXi AppTec’s addition to the US Department of Defense’s 1260H list on June 8, 2026, has triggered a 35% to 45% increase in Requests for Proposals (RFPs) across Indian CRDMOs, legacy contracts are protected until 2032. Actual order-book translation is bottlenecked by 12 to 18-month tech transfer cycles and high clinical-stage switching costs.
• Aragen’s early-to-late stage cross-selling is structurally constrained: Despite marketing a “concept-to-clinic” pipeline, Aragen’s historical core is early-stage discovery chemistry (legacy GVK Bio). Transitioning discovery clients into late-stage CDMO manufacturing is limited by a 90%+ molecule attrition rate in Phase I/II and a lack of large-scale commercial API infrastructure compared to tier-1 Indian peers.
• The US Biologics footprint (Morgan Hill) operates at a structurally lower margin: The California-based Aragen Bioscience site is confined to non-GMP early-stage cell-line development. Bridging this to the new Bengaluru (Jigani) GMP facility is operationally difficult, as US biotechs show extreme reluctance to transfer clinical-scale cell lines and process parameters across geographies due to supply chain and oversight friction.

• A leading Chinese pharmaceutical company focused on the CKM sector, engaged in R&D, production, and sales of pharmaceuticals and medical devices. It seeks a primary HKEX listing, having been listed.
• The company ranked second in China’s in-hospital cardiovascular drug sales with 11.3% market share in 2025. Total revenue increased to RMB4,352.7 million in 2025.
• Gross profit was 3,247,584 RMB’000 and profit for the year was 652,784 RMB’000 in 2025. Total assets reached 11,297,803 RMB’000 as of December 31, 2025.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Sacra estimates that Scan.com reached $165M in annualized revenue in August 2026, up from $105M at the end of 2025.
• Scan.com has raised approximately $279M in lifetime financing, comprising roughly $149M in equity and $130M in debt facilities.
• Scan.com connects patients, payers, and clinicians with independent imaging centers through a single digital layer.